Apimeds Pharmaceuticals US (APUS) Accounts Payables (2023 - 2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Accounts Payables came in at $567633.0 in Q3 2025, up 376.45% on a QoQ basis from $119138.0 in Q2 2025.

Apimeds Pharmaceuticals US (APUS) Accounts Payables (2023 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 3 years of Accounts Payables data on file, last reported at $567633.0 in Q3 2025.

Quarterly Accounts Payables changed N/A year-over-year to $567633.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $567633.0 (changed N/A YoY) and the FY2024 annual result came in at $591191.0, up 985.99% from the prior year.
Accounts Payables advanced to $567633.0 in Q3 2025, from $119138.0 in the prior quarter.
In the past five years, Accounts Payables ranged from a high of $935203.0 in Q1 2025 to a low of $54438.0 in Q4 2023.
A 3-year average of $453520.6 and a median of $567633.0 in 2025 frame the typical range for Accounts Payables.
The widest YoY moves for Accounts Payables: up 985.99% in 2024, down 985.99% in 2024.
Tracing APUS's Accounts Payables over 3 years: stood at $54438.0 in 2023, then soared by 985.99% to $591191.0 in 2024, then slipped by 3.98% to $567633.0 in 2025.
The last three Accounts Payables figures came in at $567633.0 (Q3 2025), $119138.0 (Q2 2025), and $935203.0 (Q1 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Accounts Payables (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-5.09 Bn
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	2.72 Bn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	452.00 Mn
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	2.80 Bn
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	497.80 Mn
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	1.73 Bn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	808.30 Mn
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	427.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	356.00 Mn
10	Apimeds Pharmaceuticals US	7.12 Mn	7.12 Mn	-	-

Download Data